Pharmaceutical composition containing plant extract and application of pharmaceutical composition

A technology of plant extracts and compositions is applied in the field of medicine to achieve the effects of inhibiting liver fibrosis, improving liver function and reducing collagen content

Active Publication Date: 2021-07-16
CHINA PHARM UNIV
View PDF10 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] At present, there is no report that the extract of Coleus forskohlii and the plant extract containing pentacyclic triterpenoids are used in the prevention and treatment of metabolic diseases, fibrosis diseases and liver diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing plant extract and application of pharmaceutical composition
  • Pharmaceutical composition containing plant extract and application of pharmaceutical composition
  • Pharmaceutical composition containing plant extract and application of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1 The curative effect evaluation experiment of the pharmaceutical composition of the present invention on mice with fatty liver

[0054] 1. Establishment of non-alcoholic fatty liver model mice

[0055] 100 SPF-grade male C57BL / 6 mice, 8 weeks old, weighing 18-20g, were purchased from Yangzhou University, and were adaptively raised in an SPF-grade animal room for one week. In between, maintain daily 12-h light / dark conditions. After one week of adaptive feeding, 80 mice with uniform body weight and obesity were selected and divided into 8 groups on average, namely model group, Coleus forskohlii extract group, Centella asiatica extract group, Ligustrum lucidum extract group, Birch bark extract group, Coleus forskohlii extract + Centella asiatica extract group, Coleus forskohlii extract + Ligustrum lucidum extract group, Coleus forskohlii extract + birch bark extract group. Feed with high-fat feed (containing 35% fat, 26% carbohydrate, 26% protein) for 12 weeks ...

Embodiment 2

[0079] Example 2 The curative effect evaluation experiment of the pharmaceutical composition of the present invention on mice with liver fibrosis

[0080] 1. Establishment of liver fibrosis model mice

[0081] SPF-grade male C57BL / 6 mice, 8 weeks old, weighing 18-20g, were purchased from Yangzhou University, and were adaptively bred in an SPF-grade animal room for one week. , maintain daily 12-hour light / dark conditions. 80 C57 mice were divided into 8 groups on average, 10 in each group, which were model group, Coleus forskohlii extract group, Centella asiatica extract group, Ligustrum lucidum extract group, birch bark group, hair Coleus forskohlii extract + Centella asiatica extract group, Coleus forskohlii extract + Ligustrum lucidum extract group, Coleus forskohlii extract + birch bark extract group. Every Thursday and Sunday, all mice were intraperitoneally injected with 5% carbon tetrachloride (CCl) 4 ) olive oil solution, the injection volume is calculated by 20ml / kg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for preventing, treating and improving metabolic diseases, fibrosis diseases and liver diseases. The composition at least comprises the following two active ingredients: (I) one or more of coleus forskohlii extract, forskolin and isoforskolin; and (II) one or more of a pentacyclic triterpenoid compound and a plant extract containing the pentacyclic triterpenoid compound. Compared with independent use of two components, the pharmaceutical composition disclosed by the invention can achieve a remarkable synergistic effect on prevention and treatment of the metabolic diseases, fibrosis diseases and liver diseases.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a pharmaceutical composition containing plant extracts and its application in the preparation of medicines for preventing, treating and improving metabolic diseases, fibrosis diseases and liver diseases. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD) and its subtype nonalcoholic steatohepatitis (NASH) are the leading causes of liver-related morbidity and mortality worldwide. NAFLD affects up to one-third of the world's population and may confer increased cardiometabolic risk, is characterized by insulin resistance, and is strongly associated with type 2 diabetes and obesity. NAFLD has the hallmarks of pathological ectopic fat accumulation with a mild chronic inflammatory state. Nonalcoholic steatohepatitis (NASH) is the next stage of NAFLD with an estimated prevalence of 3-5% in the general population. It is associated with visceral fat accumulation a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/53A61K36/638A61K36/734A61P3/00A61P1/16A61P3/10A61P3/06A61P3/04A61P35/00A61P9/00A61P9/10A61P13/12A61P11/00A61P17/00A61P7/10A61P19/04A61K31/352A61K31/56A61K31/7024
CPCA61K36/53A61K36/23A61K36/638A61K36/185A61K31/352A61K36/45A61K36/484A61K36/48A61K36/734A61K31/56A61K31/7024A61P3/00A61P1/16A61P3/10A61P3/06A61P3/04A61P35/00A61P9/00A61P9/10A61P13/12A61P11/00A61P17/00A61P7/10A61P19/04A61K2300/00
Inventor 吴亮
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap